ARS Pharmaceuticals, Inc. Financial Ratios
SPRY / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-149.9%
Profit Margin
-203.3%
Net Income / Revenue
Asset Turnover
0.26
Revenue / Total Assets
Equity Multiplier
2.87
Total Assets / Equity
Composite: -149.9% (reported: -149.9%)
Profitability
Liquidity
Current Ratio
7.28
Quick Ratio
6.48
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.26
Inventory Turnover
-
Days Sales Outstanding
110 days
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Earnings Quality
Accrual Ratio
-0.1%
+1.5pp YoY
Earnings are roughly in line with operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.